All treatments
Treatment
TRUQAP 160 mg film-coated tablets clinical trials
2 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic exploratory (Phase II)
A Modular Phase II, Open-Label, Multicentre Study to Assess the Efficacy and Safety of Capivasertib in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (CAPITAL)
This study is testing a new tablet medicine, Capivasertib (also called TRUQAP), for people in the UK with B-cell non-Hodgkin lymphoma that has come back or hasn't responded to previous treatments. Researchers want to see if it shrinks the cancer and if it's safe to use.
For: Relapsed or Refractory B-cell Non-Hodgkin LymphomaSpain - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Phase 1b Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination with Other Anti-cancer Agents in Patients with Metastatic HER2-low Breast Cancer (DESTINY-Breast08)
This study looks at new drug combinations for advanced breast cancer that has spread. It focuses on a type of breast cancer called 'HER2-low'. Doctors want to see if these combinations are safe, how they work in the body, and if they can help shrink tumours.
For: Metastatic Breast CancerBelgium